Illumina (NASDAQ:ILMN) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, Marketbeat reports.
A number of other brokerages also recently issued reports on ILMN. BTIG Research assumed coverage on Illumina in a report on Friday. They issued a “neutral” rating for the company. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a report on Friday. Evercore ISI assumed coverage on Illumina in a report on Wednesday. They issued an “outperform” rating and a $250.00 price target for the company. Piper Jaffray Companies boosted their price target on Illumina to $274.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Wells Fargo & Co raised Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $207.74.
Shares of Illumina (NASDAQ:ILMN) traded down $4.82 during midday trading on Friday, reaching $228.17. The company had a trading volume of 1,471,738 shares, compared to its average volume of 1,011,484. The stock has a market capitalization of $33,310.00, a price-to-earnings ratio of 43.05, a P/E/G ratio of 3.15 and a beta of 0.79. Illumina has a 52-week low of $137.40 and a 52-week high of $233.54. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 earnings per share. sell-side analysts anticipate that Illumina will post 3.75 earnings per share for the current year.
In related news, SVP Oene Mark Van sold 1,250 shares of the stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $207.21, for a total value of $259,012.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $203.27, for a total value of $4,065,400.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 158,921 shares of company stock valued at $33,810,181. 0.89% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC grew its holdings in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in Illumina in the 3rd quarter valued at $153,000. Patten Group Inc. grew its holdings in Illumina by 71.1% in the 3rd quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after buying an additional 615 shares in the last quarter. West Coast Financial LLC purchased a new stake in Illumina in the 3rd quarter valued at $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Illumina in the 2nd quarter valued at $226,000. 91.60% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/illumina-ilmn-cut-to-market-perform-at-william-blair.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.